Biomarkers along the continuum of care in lung cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Byers T, Wender RC, Jemal A, Baskies AM, Ward EE, Brawley OW. The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: results and reflections. CA Cancer J Clin 2016. [Epub ahead of print]. doi: 10.3322/caac.21348.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. 2015. v6. Available at: https://www.nccn.org. [last accessed 12 June 2016].
   Google Scholar
• Hirales Casillas CE, Flores Fernández JM, Padilla Camberos E, Herrera López EJ, Leal Pacheco G, Martínez Velázquez M. Current status of circulating protein biomarkers to aid the early detection of lung cancer. Future Oncol 2014;10:1501–13.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Small cell lung cancer. 2015. v6. Available at: https://www.nccn.org [last accessed 12 June 2016].
   Google Scholar
• Molina R, Augé JM, Bosch X, Escudero JM, Viñolas N, Marrades R, Ramírez J, Carcereny E, Filella X. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumor Biol 2009;30:121–9.
   PubMed Web of Science ®Google Scholar
• Gruber C, Hatz R, Reinmiedl J, Nagel D, Stieber P. CEA, CYFRA 21-1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach. J Lab Med 2008;32:361–71.
   Web of Science ®Google Scholar
• Stieber P, Heinemann V. Sensible use of tumor markers. J Lab Med 2008;32:339–60.
   Web of Science ®Google Scholar
• Molina R, Holdenrieder S, Auge JM, Schalhorn A, Hatz R, Stieber P. Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomark 2010;6:163–78.
   PubMed Web of Science ®Google Scholar
• Holdenrieder S, Nagel D, Stieber P. Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomark 2010;6:179–90.
   PubMed Web of Science ®Google Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472–84.
   PubMed Web of Science ®Google Scholar
• Barak V, Holdenrieder S, Nisman B, Stieber P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark 2010;6:191–6.
   PubMed Web of Science ®Google Scholar
• Holdenrieder S, Stieber P. Circulating apoptotic markers in the management of non-small cell lung cancer. Cancer Biomark 2010;6:197–210.
   PubMed Web of Science ®Google Scholar
• Trapé J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer Á, Rigo-Bonnin R. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011;49:1605–20.
   PubMed Web of Science ®Google Scholar
• Korse CM, Holdenrieder S, Zhi X, Zhang X, Qiu L, Geistanger A, Lisy MR, Wehnl B, van den Broek D, Escudero JM, Standop J, Mu H, Molina R. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. Clin Chim Acta 2015;438:388–95.
   PubMed Web of Science ®Google Scholar
• Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, MacDonald IK, Jewell W, Maddison P, Robertson JF. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biol 2012;33:1319–26.
   PubMed Web of Science ®Google Scholar
• Holdenrieder S. Circulating nucleic acids in therapy monitoring. In: Gahan PB, ed., Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring, advances in predictive, preventive and personalised medicine 5. New York: Springer; 2014:309–48.
   Google Scholar
• Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006;107:2842–9.
   PubMed Web of Science ®Google Scholar
• Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008;14:7813–21.
   PubMed Web of Science ®Google Scholar
• Ono A, Naito T, Ito I, Watanabe R, Shukuya T, Kenmotsu H, Tsuya A, Nakamura Y, Murakami H, Kaira K, Takahashi T, Kameya T, Nakajima T, Endo M, Yamamoto N. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Lung Cancer 2012;76:439–44.
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579–86.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
   PubMed Web of Science ®Google Scholar
• Freidin MB, Freydina DV, Leung M, Montero Fernandez A, Nicholson AG, Lim E. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem 2015;61:1299–304.
   PubMed Web of Science ®Google Scholar
• Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 2015;61:112–23.
   PubMed Web of Science ®Google Scholar